Alphab Global Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$4,758	1
2024	Research	$88,766	9
2023	Research	$147,395	15
2022	Research	$203,425	10
2021	Research	$100,909	13
2020	Research	$4,500	1

Breakdown

Who paid Research payments · program years 2020–2025

Otsuka Pharmaceutical Development & Commercialization, Inc. $264,922 8 payments
Janssen Research & Development, LLC $171,923 22 payments
Avanir Pharmaceuticals, Inc. $103,573 17 payments
Eli Lilly and Company $9,334 2 payments

Studies the money was for Research payments · program years 2020–2025

A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $171,923 22 payments
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury (Tbi) $146,928 3 payments
17-Avp-786-205 $97,823 15 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deuterated [D6]-Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $75,717 2 payments
A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of Avp-786 (Deuterated [D6] Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $37,278 2 payments
17-Avp-786-305 $5,750 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia $5,000 1 payment
A Randomized Double Blind Placebo Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine the Rebuild 2 Study $4,667 1 payment
A Randomized Double-Blind Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the Rebuild Study $4,667 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.